A Phase 2, Open Label, Single Arm Study To Evaluate The Efficacy, Safety, Tolerability And Pharmacokinetics Of CP-675,206 In Patients With Advanced Refractory And/Or Relapsed Melanoma
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To assess the anti-tumor efficacy, as determined by objective response rate, of intravenous CP-675,206 administered at a dose of 15 mg/kg every 90 days to patients with relapsed or refractory advanced melanoma
Tumor response is assessed every 2-3 months until disease progression
No
United States: Food and Drug Administration
A3671008
NCT00254579
December 2005
December 2009
Name | Location |
|---|---|
| Pfizer Investigational Site | Cincinnait, Ohio 45236 |
| Research Site | Mesa, Arizona |
| Research Site | Bentonville, Arkansas |
| Research Site | Anaheim, California |
| Research Site | Boulder, Colorado |
| Research Site | Danbury, Connecticut |
| Research Site | Boca Raton, Florida |
| Research Site | Arlington Heights, Illinois |
| Research Site | Bloomington, Indiana |
| Research Site | Ashland, Kentucky |
| Research Site | Baltimore, Maryland |
| Research Site | Beverly, Massachusetts |
| Research Site | Battle Kreek, Michigan |
| Research Site | Albany, New York |
| Research Site | Asheville, North Carolina |
| Research Site | Akron, Ohio |
| Research Site | Allentown, Pennsylvania |
| Research Site | Chattanooga, Tennessee |
| Research Site | Ivins, Utah |
| Research Site | Auburn, Washington |
| Research Site | Appleton, Wisconsin |